DOCSLIB.ORG

Intellia Therapeutics Annual Report 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intellia Therapeutics Annual Report 2021 Intellia Therapeutics Annual Report 2021 Form 10-K (NASDAQ:NTLA) Published: February 26th, 2021 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (857) 285-6200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trade Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $1,182,698,098 as of June 30, 2020 (based on a closing price of $21.02 per share as quoted by the Nasdaq Global Market as of such date). In determining the market value of non-affiliate common stock, shares of the registrant’s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The registrant had 67,726,345 shares of Common Stock, $0.0001 par value per share, outstanding as of February 19, 2021. DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant’s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year end of December 31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K. Intellia Therapeutics, Inc. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2020 Table of Contents Item No. PART I Page Item 1. Business 6 Item 1A. Risk Factors 38 Item 1B. Unresolved Staff Comments 86 Item 2. Properties 87 Item 3. Legal Proceedings 87 Item 4. Mine Safety Disclosures 88 PART II Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 89 Item 6. Selected Financial Data 91 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 92 Item 7A. Quantitative and Qualitative Disclosures about Market Risk 101 Item 8. Financial Statements and Supplementary Data 101 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 101 Item 9A. Controls and Procedures 101 Item 9B. Other Information 104 PART III Item 10. Directors, Executive Officers and Corporate Governance 105 Item 11. Executive Compensation 105 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 105 Item 13. Certain Relationships and Related Transactions, and Director Independence 105 Item 14. Principal Accounting Fees and Services 105 PART IV Item 15. Exhibits, Financial Statement Schedules 106 Item 16. Form 10-K Summary 106 Signatures Forward-looking Information This Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward- looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: • our ability to execute our clinical study strategy for NTLA-2001, our program for the treatment of transthyretin amyloidosis; • the anticipated timing of preclinical studies, manufacturing activities, our investigational new drug application (“IND”) or equivalent regulatory filing, and clinical studies for NTLA-5001, our program for the treatment of acute myeloid leukemia; • the anticipated timing of preclinical studies, manufacturing activities, our IND application or equivalent regulatory filing, and clinical studies for NTLA-2002, our program for the treatment of hereditary angioedema; • our ability to use a modular platform capability or other strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs; • our ability to research, develop or maintain a pipeline of product candidates; • our ability to manufacture or obtain material for our preclinical and clinical studies, and our product candidates; • our ability to advance any product candidates into, and successfully complete, clinical studies, including clinical studies necessary for regulatory approval and commercialization, and to demonstrate to the regulators that the product candidates are safe, effective, pure and potent and that their benefits outweigh known and potential risks for the intended patient population; • our ability to advance our genome editing and therapeutic delivery capabilities; • the scope of protection we are able to develop, establish and maintain for intellectual property rights, including patents and license rights, covering our product candidates and technology; • our ability to operate, including commercializing products, without infringing or breaching the proprietary or contractual rights of others; • the issuance or enforcement of, and compliance with, regulatory requirements and guidance regarding preclinical and clinical studies relevant to genome editing and our product candidates; • the market acceptance, pricing and reimbursement of our product candidates, if approved; • estimates of our expenses, future revenues, capital requirements and our needs for additional financing; • the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; • our ability to maintain and establish collaborations with third parties under favorable terms; • our ability to acquire and maintain relevant intellectual property licenses and rights, and the scope and terms of such rights; • developments relating
Load more

Recommended publications
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2020 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (857) 285-6200 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol(s) on which registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    [Show full text]
  • Questions About CRISPR
    CRISPR Questions about CRISPR A huge industry will grow from its innovation, but the IP environment around CRISPR is far from established. Marc Döring and Daniel Lim investigate The discovery of the potential of CRISPR and its first Cas system for various applications. characterisation in the form of the CRISPR/Cas9 system One group comprises Intellia, Caribou Biosciences (Caribou), represents a true revolution in the life sciences field. It is best Caribou founder Jennifer Doudna and the University of California, known as a method that allows for the accurate and targeted cutting Berkeley (UCB). That group is broadly aligned with CRISPR Tx, ERS of DNA to enable editing of genes, but variants can accomplish a Genomics and its founder Emmanuelle Charpentier, who collaborated wide range of other extremely useful effects, including modulation of with Doudna and co-owner of UCB’s foundational CRISPR patents. On gene expression. The power and versatility of the system has opened 16 December 2016, the Doudna and Charpentier camps formalised the door to advances in a wide range of industries, including human their alliance, signing a global cross-licensing and patent prosecution therapeutics, animal health, agriculture and bioindustry. CRISPR has the co-operation agreement. potential to revolutionise any industry in which molecular biology and Opposing them is Editas, its founder Feng Zhang and the Broad genetic technology play a part. Institute of MIT and Harvard (the Broad), who hold a separate, However, despite the clear potential of the technology, and leaving competing portfolio of foundational CRISPR/Cas9 patents. aside the significant amount of research and development still to be These spin-out companies have wasted no time in partnering undertaken, question marks linger over the legal and regulatory position variously with big pharma, venture capitalists and fellow disruptive of CRISPR technology and CRISPR-based products.
    [Show full text]
  • Market Deep Dive Report CRISPR Therapeutics June 2020
    Market Deep Dive Report CRISPR Therapeutics June 2020 Contents 1. Summary 3 2. Market Overview 3 2.1 Industry Challenges 4 2.2 Intellectual Property 5 2.3 Regulatory Requirements 5 2.4 Pitchbook Market Statistics 6 3. Technology Overview 6 3.1 Basic Summary 6 3.2 Base Editing 7 3.3 Prime Editing 8 3.4 Ex-Vivo CRISPR 9 3.5 In-Vivo CRISPR 10 3.6 Alternative techniques and platforms 11 3.7 Late stage privates & publics 13 3.8 Key People and Labs 13 4. Therapeutic Landscape 14 4.1 Present day status 14 4.2 Future Indications 16 4.3 Startups to Watch 17 5. Conclusions 18 5.1 Vertical Strengths 18 5.2 Vertical Weaknesses 18 5.3 Opportunity Cost of Capital 19 5.4 Investment Theses 19 6. References 20 2 1. Summary Since its initial discovery as a genetic reprogramming tool in 2012, CRISPR has widely been regarded as a breakthrough scientific discovery and quickly become one of the hottest new biotechnologies in the industry. However, the CRISPR therapeutics market is still in early stages, with leading therapies only just reaching human clinical trials. Furthermore, the industry is highly defended by IP, and currently addresses a narrow set of indications. Top companies including Beam Therapeutics, Editas Medicine, and Prime Medicine have been founded by the same scientists, and have formed a highly collaborative moat. Remaining companies have partnered with large pharmaceutical companies to fund operations. The future of CRISPR therapeutics development is dependent on technological advances in delivery methods and editing safety and granularity.
    [Show full text]
  • News & Analysis
    NEWS & ANALYSIS NEWS IN BRIEF Intellia Therapeutics and partner Alzheimer prevention failure rattles field, anew Regeneron are working towards a 2020 investigational new drug application for Failed trials of amyloid- modulating Alzheimer disease candidates don’t come as much of a their in vivo NTLA-2001, a systemically surprise any more. But with Amgen and Novartis’s recent decision to halt two phase III trials delivered CRISPR treatment for transthyretin of the BACE1 inhibitor umibecestat for secondary prevention of the neurodegenerative amyloidosis. disease in high-risk patients, a longer shadow has now fallen on the prospects for these Asher Mullard agents in earlier lines of treatment as well. In the Generation S1 trial, the sponsors were testing umibecestat and the amyloid vaccine CAD106 in cognitively unimpaired individuals aged 60 to 75 years with two APOE4 genes, a risk factor for developing Alzheimer disease. In Generation S2, they were testing Longer- lasting HIV drugs umibecestat in cognitively unimpaired participants aged 60 to 75 years with at least one Antiretroviral therapies have revolutionized APOE4 allele. But in July the companies announced that the drug was associated with AIDS care, changing what was once a death worsening in some measures of cognitive function, and discontinued development of the sentence into a chronic and controllable BACE inhibitor. condition. But antiretroviral therapy (ART) After past failures of amyloid-modulating drugs, researchers have posited that these cocktails still have to be taken on a daily agents need to be used earlier in the course of disease — potentially years before symptoms basis, and treatment interruptions can result are detectable — to prevent neuronal death.
    [Show full text]
  • CRISPR Genome-Editing
    CRISPR Genome-Editing The Value of CRISPR’s IP Published: August 17, 2018 Author Manisha Samy, Analyst at ARK Invest Join the conversation on Twitter @ARKinvest www.ark-invest.com The Value of CRISPR’s Intellectual Property Manisha Samy THE VALUE OF INTELLECTUAL PROPERTY Intellectual property (IP) can be critical not only to commercial success but also to platform strategies upon which more innovation can take place. A strong patent portfolio might not guarantee success, but it can serve as a strategic asset, particularly in biotech. Patents provide a company with 20 years of exclusivity to advance innovations before others can compete. In the meantime, these companies receive licensing fees and/or royalty payments, but perhaps more importantly, attract talent seeking unfettered access to cutting edge technology. Genentech is a prime example of the benefits of a strong IP position in the field of health care. In 1980, Genentech went public, largely on the strength of its IP in recombinant DNA technology.1 Attracting some of biotech’s brightest minds, it commercialized synthetic insulin two years later, four years before Roche took a majority interest. Genentech’s stock scaled 11-fold at a 47% compound annual rate in the six years between its initial public offering (IPO) and Roche taking majority interest. CRISPR’S IP LANDSCAPE While Genentech benefited from a patent claim that was unambiguous, the CRISPR IP landscape is much more convoluted. In a high-profile patent battle between the University of California (UC), Berkeley and the Broad Institute, scientists are fighting for commercial claims to the “foundational” CRISPR IP.
    [Show full text]
  • CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S
    CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology in all environments that do not interfere with the Broad’s patent claims in this proceeding Additional legal paths are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells University of California/University of Vienna/Dr. Charpentier were recently issued a U.S. patent for the use of CRISPR/Cas9 genome editing that covers guide formats widely used across the human therapeutic and agricultural industries ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affirmed the decision by the U.S. Patent and Trademark Office’s (“USPTO”) Patent Trial and Appeal Board (“PTAB”) in an interference proceeding relating to CRISPR/Cas9 genome editing technology. The interference was requested by the Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, against the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively “Broad”).
    [Show full text]
  • INTELLIA THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 INTELLIA THERAPEUTICS, INC. (Name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: INTELLIA THERAPEUTICS, INC.
    [Show full text]
  • Nobel Laureate Jennifer Doudna and the Bio Revolution Catalyst COLLEGE of CHEMISTRY UNIVERSITY of CALIFORNIA, BERKELEY
    SP21 V 16.1 Spring/Summer 2021 Volume 16 • Issue 1 COLLEGE OFCatalyst CHEMISTRY • UNIVERSITY OF CALIFORNIA, BERKELEY Nobel Laureate Jennifer Doudna and the bio revolution Catalyst COLLEGE OF CHEMISTRY UNIVERSITY OF CALIFORNIA, BERKELEY dean Douglas S. Clark [email protected] executive associate dean Richmond Sarpong [email protected] chair, department of chemistry Matthew B. Francis [email protected] chair, department of chemical and biomolecular engineering Jeffrey A. Reimer [email protected] undergraduate dean John Arnold [email protected] senior assistant dean, college relations & development 7 Laurent “Lo” de Janvry [email protected] senior director of development Mindy Rex [email protected] senior director, strategic and philanthropic partnerships Camille M. Olufson [email protected] managing editor director marketing and communications Marge d’Wylde catalyst online Leigh Moyer contributors 12 Ashok Ajoy Laurent de Janvry Denise Klarquist Mark Kubinec Brice Yates research Sara Koerber design Alissar Rayes printing Dome Printing for submissions to college publications, please email content to: [email protected] 6 ON THE COVER In this issue, we celebrate Professor Jennifer Doudna’s Nobel Prize and the bio revolution she has helped create. COVER PHOTO: KEEGAN HOUSER catalyst online at: catalyst.berkeley.edu © 2021, Regents of the University of California contents Spring/Summer 2021 Volume 16 • Issue 1 3 DEAN’S DESK 16 The new era in theoretical chemistry 4 NEW & NOTABLE 18 MARTIN HEAD-GORDON 20 BIRGITTA WHALEY 8 FUTURE TECH 22 PHILLIP GEISSLER 24 ERAN RABANI 12 Nobel Laureate Jennifer Doudna and the bio revolution 26 NEW FACULTY PROFILES 32 DONOR SPOTLIGHT 36 EDITORIAL 16 32 26 28 30 36 College of Chemistry, UC Berkeley PHOTO © BENSONPHOTOS, ALL RIGHTS RESERVED.
    [Show full text]
  • CRISPR Steps Closer to Centre Stage As Astrazeneca Piles In
    January 29, 2015 CRISPR steps closer to centre stage as AstraZeneca piles in Amy Brown Maxed out on CAR-T and looking for the next field of novel and cutting-edge science to capture the imagination of investors? Look no further than CRISPR, the hot gene-editing technology with a rapidly rising profile, into which AstraZeneca swooped today in a pretty big way. True, CRISPR is at an even earlier stage than CAR-T and its therapeutic applications are considerably further from the market. But the fields are connected – some CAR-T companies are using gene-editing techniques – and also display similarities; the largely academic-led space has been born of much scientific cross-fertilisation, and IP squabbles loom large. As long as the stock markets remain so receptive to risk, it will surely not be long before public investors can get involved. Currently there are only three companies, all private, that have declared a dedication to the use of CRISPR to develop drugs: Editas Medicine, Intellia Therapeutics and Crispr Therapeutics. CRISPR, a third-generation gene-editing technology, follows in the wake of zinc finger and TALEN platforms. The idea is the same, although rather than using large, unwieldy proteins to guide a DNA-cutting enzyme to its target, like the earlier incarnations, CRISPR uses tiny strands of RNA. The result is a much more precise tool that allows multiple genetic deletions or edits to be made, with huge implications for the cost and time of experiments. So it is not surprising that CRISPR has attracted a fair amount of commercial interest in a very short space of time.
    [Show full text]
  • INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter) Delaware 36-4785571 (State Or Other Jurisdiction of (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (857) 285-6200 (Registrants telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trade Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Zafgen Charts Unique Path to Obesity Approval
    NEWS & ANALYSIS NEWS IN BRIEF Novartis secures first CRISPR pharma collaborations EMA recommended approval Two deals from Novartis show that industry is ready to embrace the gene-editing CRISPR–Cas9 for 40 new drugs in 2014 technology into its target-screening, target-validation and therapeutic tool-box. In a deal with Intellia Therapeutics, Novartis gained exclusive rights to use Intellia’s The European Medicines Agency (EMA) CRISPR gene-editing technology to engineer chimeric antigen receptor T-cells (CAR‑Ts) and approved 40 new agents in 2014, up from haematopoietic stem cells (HSCs). Novartis, a leader in the CAR‑T field, is already developing 34 in 2013. This left the European regulators its CTL019 CAR‑T treatment, which is made up of autologous T-cells that express the only one approval behind the US Food and CD19-specific CAR, in Phase II trials in chronic lymphocytic leukaemia, acute lymphocytic Drug Administration (FDA) last year (see leukaemia and diffuse large B-cell lymphoma. Novartis has also been expanding into the HSC Nature Rev. Drug Discov. 14, 77–81; 2015 for space, and last year bought into Gamida Cell, who are developing a CD133+ HSC product for detailed analysis of the FDA’s approvals in use in leukaemia, lymphoma and sickle-cell disease. 2014). Both regulatory bodies set records with Separately, Novartis partnered with Caribou Biosciences, gaining access to Caribou’s orphan-drug approvals, with each giving the CRISPR–Cas9 platform “to research new CRISPR-based drug target screening and validation green light to 17 agents for rare diseases. technologies”. Caribou, which is developing CRISPR–Cas9 research tools for multiple sectors, Although there was considerable overlap including industrial and agricultural biotech, is a co-founder of Intellia.
    [Show full text]